516 related articles for article (PubMed ID: 33589525)
1. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
2. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
Campbell JR; McDonald BR; Mesko PB; Siemers NO; Singh PB; Selby M; Sproul TW; Korman AJ; Vlach LM; Houser J; Sambanthamoorthy S; Lu K; Hatcher SV; Lohre J; Jain R; Lan RY
Cancer Res; 2021 Jun; 81(11):2983-2994. PubMed ID: 33757978
[TBL] [Abstract][Full Text] [Related]
3. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
4. CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function.
Whiteside SK; Grant FM; Gyori DS; Conti AG; Imianowski CJ; Kuo P; Nasrallah R; Sadiyah F; Lira SA; Tacke F; Eil RL; Burton OT; Dooley J; Liston A; Okkenhaug K; Yang J; Roychoudhuri R
Immunology; 2021 Aug; 163(4):512-520. PubMed ID: 33838058
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.
Weaver JD; Stack EC; Buggé JA; Hu C; McGrath L; Mueller A; Wong M; Klebanov B; Rahman T; Kaufman R; Fregeau C; Spaulding V; Priess M; Legendre K; Jaffe S; Upadhyay D; Singh A; Xu CA; Krukenberg K; Zhang Y; Ezzyat Y; Saddier Axe D; Kuhne MR; Meehl MA; Shaffer DR; Weist BM; Wiederschain D; Depis F; Gostissa M
Oncoimmunology; 2022; 11(1):2141007. PubMed ID: 36352891
[TBL] [Abstract][Full Text] [Related]
6. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
[TBL] [Abstract][Full Text] [Related]
7. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
8. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory.
Kidani Y; Nogami W; Yasumizu Y; Kawashima A; Tanaka A; Sonoda Y; Tona Y; Nashiki K; Matsumoto R; Hagiwara M; Osaki M; Dohi K; Kanazawa T; Ueyama A; Yoshikawa M; Yoshida T; Matsumoto M; Hojo K; Shinonome S; Yoshida H; Hirata M; Haruna M; Nakamura Y; Motooka D; Okuzaki D; Sugiyama Y; Kinoshita M; Okuno T; Kato T; Hatano K; Uemura M; Imamura R; Yokoi K; Tanemura A; Shintani Y; Kimura T; Nonomura N; Wada H; Mori M; Doki Y; Ohkura N; Sakaguchi S
Proc Natl Acad Sci U S A; 2022 Feb; 119(7):. PubMed ID: 35140181
[TBL] [Abstract][Full Text] [Related]
9. S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells.
Nagira Y; Nagira M; Nagai R; Nogami W; Hirata M; Ueyama A; Yoshida T; Yoshikawa M; Shinonome S; Yoshida H; Haruna M; Miwa H; Chatani N; Ohkura N; Wada H; Tanaka H
Mol Cancer Ther; 2023 Sep; 22(9):1063-1072. PubMed ID: 37420296
[TBL] [Abstract][Full Text] [Related]
10. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.
Knitz MW; Bickett TE; Darragh LB; Oweida AJ; Bhatia S; Van Court B; Bhuvane S; Piper M; Gadwa J; Mueller AC; Nguyen D; Nangia V; Osborne DG; Bai X; Ferrara SE; Boss MK; Goodspeed A; Burchill MA; Tamburini BAJ; Chan ED; Pickering CR; Clambey ET; Karam SD
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883256
[TBL] [Abstract][Full Text] [Related]
11. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
12. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
13. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
[TBL] [Abstract][Full Text] [Related]
14. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
[TBL] [Abstract][Full Text] [Related]
15. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.
Dodagatta-Marri E; Meyer DS; Reeves MQ; Paniagua R; To MD; Binnewies M; Broz ML; Mori H; Wu D; Adoumie M; Del Rosario R; Li O; Buchmann T; Liang B; Malato J; Arce Vargus F; Sheppard D; Hann BC; Mirza A; Quezada SA; Rosenblum MD; Krummel MF; Balmain A; Akhurst RJ
J Immunother Cancer; 2019 Mar; 7(1):62. PubMed ID: 30832732
[TBL] [Abstract][Full Text] [Related]
16. Curcumin analog GO-Y030 boosts the efficacy of anti-PD-1 cancer immunotherapy.
MaruYama T; Kobayashi S; Shibata H; Chen W; Owada Y
Cancer Sci; 2021 Dec; 112(12):4844-4852. PubMed ID: 34529884
[TBL] [Abstract][Full Text] [Related]
17. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
[No Abstract] [Full Text] [Related]
18. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589
[TBL] [Abstract][Full Text] [Related]
19. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
20. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
Xue W; Brentville VA; Symonds P; Cook KW; Yagita H; Metheringham RL; Durrant LG
Oncotarget; 2016 Dec; 7(50):83088-83100. PubMed ID: 27825115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
